Revisiting platinum-resistant ovarian cancer: Advances in therapy, molecular biomarkers, and clinical outcomes-Reference-Cited by-同舟云学术

Revisiting platinum-resistant ovarian cancer: Advances in therapy, molecular biomarkers, and clinical outcomes

Published:2021-12 Issue: Volume:77 Page:1-2
ISSN:1044-579X
Container-title:Seminars in Cancer Biology
language:en
Short-container-title:Seminars in Cancer Biology

Author:

El Bairi Khalid,Singh Seema,Le Page Cécile

Publisher

Elsevier BV

Subject

Cancer Research

Reference15 articles.

1. The forefront of ovarian cancer therapy: update on PARP inhibitors;Mirza;Ann. Oncol.,2020

2. PARP inhibitors in the management of ovarian cancer: ASCO guideline;Tew;J. Clin. Oncol.,2020

3. Does the “Devil” originate from the fallopian tubes?;El Bairi;Semin. Cancer Biol.,2021

4. Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2 mutation carriers;Le Page;Semin. Cancer Biol.,2020

5. Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?;Funingana;Semin. Cancer Biol.,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer;JOVE-J VIS EXP;2024

2. New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings;International Journal of Gynecologic Cancer;2023-12-14

3. Emerging roles of circ_NRIP1 in tumor development and cancer therapy (Review);Oncology Letters;2023-06-08